CKB (Creatine Kinase B-type) is a key enzyme in cellular energy metabolism, catalyzing the reversible transfer of phosphate between ATP and creatine to regulate energy homeostasis. It is highly expressed in tissues with dynamic energy demands, such as the brain, heart, and skeletal muscle. CKB antibodies are essential tools for studying its expression, localization, and functional roles in physiological and pathological contexts.
Research has linked CKB dysregulation to various diseases. In cancer, elevated CKB levels are observed in tumors like breast and colorectal cancers, where it may support tumor growth by buffering energy stress. In neurodegenerative disorders (e.g., Alzheimer’s disease), altered CKB expression is associated with synaptic dysfunction. Cardiovascular studies suggest its involvement in ischemic injury response.
CKB antibodies, typically generated using recombinant proteins or peptide immunogens, enable detection via techniques like Western blot, immunohistochemistry, and immunofluorescence. Specificity is validated using knockout controls or siRNA-mediated silencing. Commercial CKB antibodies are widely available, but batch variability necessitates careful validation for experimental reproducibility.
Overall, CKB antibodies are critical for exploring the enzyme’s dual roles as a metabolic regulator and disease biomarker, bridging energy metabolism research with therapeutic discovery.